Anti-CLEC2 [AYP2]
Invented at University Of Birmingham
Catalogue Number | 151913 |
Applications | FACS IF IP Fn |
Antigen/Gene or Protein Targets | C-type lectin-like receptor 2, CLEC1b |
Reactivity | Human |
Relevance | Patients with rheumatoid arthritis, an inflammatory disease associated with increased microparticle production, have raised plasma levels of microparticles that expressed CLEC-2 but not GPVI. CLEC-2 can be used to monitor platelet-derived microparticles. The observation that microparticles derived from activated platelets retain CLEC-2 but lose GPVI highlights the potential use of measurement of surface expression of platelet receptors to screen for platelet activation in a wide variety of cardiovascular and inflammatory diseases. |
Host | Mouse |
Immunogen | A recombinant extracellular fragment of human CLEC-2 (aa 68-229), which is the extracellular domain of the protein |
Positive Control | Platelets |
Subclass | IgG1 |
Molecular Weight (kDa) | 26 |
Myeloma Used | Sp2/0-Ag14 |
Recommended Growing Conditions | Hybridomas were cultured at 37ยบ C and 96% relative humidity in air containing 6% CO2. Cells were grown in complete DMEM + Pen/strep + FCS was used at 10%. Cell density: Cells should be kept between 1-2x105 cells/ml and 5x105 cells/ml. |
Notes |
AYP1 can block the interaction of human CLEC-2 with its endogenous ligand Podoplanin. AYP1 does not cross react with mouse CLEC-2 when tested via FACS. AYP1 does not detect CLEC-2 by western blot. For WB we recommend clone AYP2. |
Research Area | Cardiovascular, Immunology |
Gitz et al. 2014. Blood. 124(14):2262-70. PMID: 25150298.
CLEC-2 expression is maintained on activated platelets and on platelet microparticles.
Europe PMC ID: 25150298
Gitz et al. 2014. Blood. 124(14):2262-70. PMID: 25150298.
CLEC-2 expression is maintained on activated platelets and on platelet microparticles.